Staff Profile

Educational Qualification

MBBS, Master of Public Health, Post graduate Diploma in Bio Ethics and Medical Ethics.

Personal Statement

Actively involved in research studies in line with WHO, NTEP & ICMR research priorities focusing on emerging scientific principles towards TB elimination goals for the past 2 decades. Member Secretary of the Institutional Ethics Committee of ICMR-NIRT. Co-ordinated many multi-centric TB & HIV drug trials & pharmacokinetic studies as PI which has created evidence for significant policy change in the country.

Research Focus

• • RCTs on High dose Rifampicin and other TB drugs
• • TB Preventive Therapy studies on household contacts of Drug sensitive & resistant TB patients.
• • Post TB lung disease and Pulmonary Rehabilitation studies.

Ongoing projects as Principal investigator

1. A Multi-centric Parallel arm Randomized Clinical trial to improve treatment outcomes among persons with drug sensitive pulmonary TB treated with 4 or 6 months of High dose Rifampicin containing regimens with or without Levofloxacin (PRaCTISe-HR)

2. Effect of pulmonary rehabilitation with respiratory physiotherapy during the continuation phase of tuberculosis treatment on the exercise tolerance among patients with sputum positive pulmonary tuberculosis

3. The Regional Prospective Observational Research for Tuberculosis (Report) India Phase II Common Protocol

Significant Publications

* Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. PMID: 38444824; PMCID: PMC10914527.

* Bhavani Perumal Kannabiran, Jayanthi Arthanari, Adhin Bhaskar, Mukesh Kumar Sathya Narayanan, Leeberk Raja Inbaraj,Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis, Systematic Review 161(5);449-460doi:10.25259/IJMR_1673_2024 Received: 2024-10-22, Accepted: 2025-04-28, Epub ahead of print: 2025-06-26, Published: 2025-06-30

* Kathamuthu GR, Bhavani PK, Singh M, Saini JK, Aggarwal A, Ansari MSS, Garg R, Babu S. High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis. Front Pharmacol. 2022 Jul 15;13:896551. doi: 10.3389/fphar.2022.896551. PMID: 35910352; PMCID: PMC9335011.

Shorter treatment for nonsevere tuberculosis in African and Indian children A Turkova, GH Wills, E Wobudeya, C Chabala, M Palmer, A Kinikar, ...New England Journal of Medicine 386 (10), 911-922

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial, C Chabala, A Turkova, MJ Thomason, E Wobudeya, S Hissar, V Mave, ... Trials 19 (1), 237

* Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol …C Padmapriyadarsini, PK Bhavani, M Natrajan, C Ponnuraja, H Kumar, ...BMJ open 9 (3), e024363

Pandiarajan AN, Kumar NP, Rajamanickam A, Bhavani PK, Jeyadeepa B, Selvaraj N, Asokan D, Tripathy S, Padmapriyadarsini C, Babu S. Enhanced Antimicrobial Peptide Response Following Bacillus Calmette-Guerin Vaccination in Elderly Individuals. Vaccines (Basel). 2024 Sep 18;12(9):1065. doi: 10.3390/vaccines12091065. PMID: 39340094; PMCID: PMC11436028.

Kumar AKH, Kadam A, Karunaianantham R, Tamizhselvan M, Padmapriyadarsini C, Mohan A, Jeyadeepa B, Radhakrishnan A, Singh UB, Bapat S, Mane A, Kumar P, Mamulwar M, Bhavani PK, Haribabu H, Rath N, Guleria R, Khan AM, Menon J;METRIF Team. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis. Ther Drug Monit. 2024 Jun 1;46(3):370-375. doi:10.1097/ FTD. 0000000000001149. Epub 2023 Nov 28. PMID: 38019456; PMCID: PMC11078288.

Shewade, Hemant D.1, Frederick, Asha2, Kalyanasundaram, Madhanraj3,Chadwick, Joshua3,Kiruthika, Rajasekar, T Daniel,Gayathri, K3, Vijayaprabha, Sabarinathan, Shivakumar, Shri Vijay Bala Yogendra, Jeyashree, Kathiresan, Bhavani, P K, Aarthi, , Suma, K V, Pathinathan, Delphina P. Parthasarathy, Raghavan, Nivetha, M Bhavani , Thampi, Jerome G, et. al. Triaging for Severe Illness amongst Adults with Tuberculosis Followed by Referral and Inpatient Care: A Statewide Pilot in Tamil Nadu, India. Preventive Medicine Research & Reviews 1(2):p 94-101, Mar–Apr 2024. | DOI: 10.4103/PMRR.PMRR_33_23

Hamada Y, Quartagno M, Malik F, Ntshamane K, Tisler A, Gaikwad S, Carlos Acuna-Villaorduna, Perumal Kannabiran Bhavani et al. Prevalence of non-communicable diseases among household contacts of people with tuberculosis: A systematic review and individual participant data meta-analysis. Trop Med Int Health. 2024; 29(9): 768–780. https://doi.org/10.1111/tmi.14038

Effect of antiretroviral therapy on retention of people living with HIV in India (2012–2017): a retrospective, cohort study, Chidrawar, Shweta Godbole, Sheela et al., The Lancet Regional Health - Southeast Asia, Volume 34, 100552

Research Profiles